Prostate Cancer Stocks List



Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Recent Signals

Date Stock Signal Type
2021-07-23 ABBV Three Weeks Tight Range Contraction
2021-07-23 ABBV New 52 Week High Strength
2021-07-23 ABBV NR7 Range Contraction
2021-07-23 ABBV New 52 Week Closing High Bullish
2021-07-23 ABBV Stochastic Reached Overbought Strength
2021-07-23 ACHV Calm After Storm Range Contraction
2021-07-23 ACHV NR7 Range Contraction
2021-07-23 ACHV Narrow Range Bar Range Contraction
2021-07-23 ADMP Fell Below 20 DMA Bearish
2021-07-23 AFMD Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-07-23 AFMD Crossed Above 200 DMA Bullish
2021-07-23 AFMD MACD Bullish Signal Line Cross Bullish
2021-07-23 AFMD 1,2,3 Retracement Bearish Bearish Swing Setup
2021-07-23 AMGN Bollinger Band Squeeze Range Contraction
2021-07-23 AMGN Crossed Above 20 DMA Bullish
2021-07-23 AYTU Stochastic Reached Oversold Weakness
2021-07-23 AYTU New 52 Week Closing Low Bearish
2021-07-23 BLCM NR7 Range Contraction
2021-07-23 BLCM Narrow Range Bar Range Contraction
2021-07-23 BNR MACD Bearish Signal Line Cross Bearish
2021-07-23 CBLI Narrow Range Bar Range Contraction
2021-07-23 CBLI Fell Below 200 DMA Bearish
2021-07-23 CBLI NR7 Range Contraction
2021-07-23 CBLI Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-07-23 CRDF Doji - Bullish? Reversal
2021-07-23 ENDP Calm After Storm Range Contraction
2021-07-23 ENDP Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-07-23 HARP MACD Bearish Signal Line Cross Bearish
2021-07-23 HARP Stochastic Reached Oversold Weakness
2021-07-23 HARP Calm After Storm Range Contraction
2021-07-23 HARP Jack-in-the-Box Bearish Bearish Swing Setup
2021-07-23 HARP Lower Bollinger Band Walk Weakness
2021-07-23 INO MACD Bearish Centerline Cross Bearish
2021-07-23 INO Fell Below 50 DMA Bearish
2021-07-23 INO 20 DMA Resistance Bearish
2021-07-23 IONS 50 DMA Support Bullish
2021-07-23 IONS Crossed Above 20 DMA Bullish
2021-07-23 JAZZ NR7 Range Contraction
2021-07-23 LNTH Pocket Pivot Bullish Swing Setup
2021-07-23 LNTH Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-07-23 MYGN Bollinger Band Squeeze Range Contraction
2021-07-23 MYGN 20 DMA Support Bullish
2021-07-23 MYGN Bearish Engulfing Bearish
2021-07-23 MYOV 200 DMA Resistance Bearish
2021-07-23 MYOV MACD Bullish Signal Line Cross Bullish
2021-07-23 MYOV Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-07-23 MYOV 20 DMA Resistance Bearish
2021-07-23 NUVB NR7 Range Contraction
2021-07-23 PDSB Fell Below 50 DMA Bearish
2021-07-23 PROF Hammer Candlestick Bullish
2021-07-23 PROF Doji - Bullish? Reversal
2021-07-23 PROF Lizard Bullish Bullish Day Trade Setup
2021-07-23 RAIN Fell Below 20 DMA Bearish
2021-07-23 RAIN MACD Bearish Signal Line Cross Bearish
2021-07-23 RAIN Fell Below 50 DMA Bearish
2021-07-23 SGEN Stochastic Buy Signal Bullish
2021-07-23 SNY Bollinger Band Squeeze Range Contraction
2021-07-23 SNY Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-07-23 SNY Pocket Pivot Bullish Swing Setup
2021-07-23 SNY 20 DMA Resistance Bearish
2021-07-23 SPPI Stochastic Reached Oversold Weakness
2021-07-23 VACC MACD Bearish Centerline Cross Bearish
2021-07-23 XOMA 20 DMA Resistance Bearish

Prostate Cancer Stocks Recent News

Date Stock Title
Jul 26 ABBV The Smartest Dividend Aristocrats to Buy With $500 Right Now
Jul 26 EXEL 5 No-Brainer Stocks to Invest $500 In Right Now
Jul 26 BNR Calculating The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)
Jul 26 ABBV AbbVie's AGN-190584 shows promising action in late-stage presbyopia study
Jul 26 ABBV 15 Best Warren Buffett Stocks to Buy Now
Jul 25 ABBV New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
Jul 25 ABBV The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Jul 25 IONS The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Jul 25 LNTH The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Jul 25 MYOV The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Jul 25 OPK The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Jul 25 SGEN The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Jul 25 ABBV Wall Street Breakfast: The Week Ahead
Jul 25 ABBV 3 Dividend Stocks to Buy Hand Over Fist If the Market Crashes
Jul 25 JAZZ Has Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's Recent Performance Got Anything to Do With Its Financial Health?
Jul 25 ENDP NRx Pharma, Cassava Sciences lead weekly healthcare gainers; Seres Therapeutics trail
Jul 24 ABBV Stocks To Watch: Apple And Tesla Lead Earnings Blitz, New IPOs And SPAC Debuts
Jul 24 AFMD 3 Biotech Stocks That Could Rocket Higher
Jul 24 JAZZ Is Jazz Pharmaceuticals Stock a Buy?
Jul 24 ABBV 3 Value Stocks to Buy for the Second Half of 2021

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

More about Prostate Cancer
Browse All Tags